U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H25F3N4O3S
Molecular Weight 482.519
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of JNJ-41443532

SMILES

O[C@]1(CC[C@@H](CC1)N2CC(C2)NC(=O)CNC(=O)C3=CC=CC(=C3)C(F)(F)F)C4=CN=CS4

InChI

InChIKey=CFKBNYUHQSQBSX-CYWCHRQTSA-N
InChI=1S/C22H25F3N4O3S/c23-22(24,25)15-3-1-2-14(8-15)20(31)27-10-19(30)28-16-11-29(12-16)17-4-6-21(32,7-5-17)18-9-26-13-33-18/h1-3,8-9,13,16-17,32H,4-7,10-12H2,(H,27,31)(H,28,30)/t17-,21-

HIDE SMILES / InChI
JNJ-41443532 is a C-C motif chemokine receptor 2 antagonist. It is under development for the treatment of type 2 diabetes.

Approval Year

PubMed

PubMed

TitleDatePubMed
CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
2014-11
Patents
Name Type Language
BENZAMIDE, N-(2-((1-(TRANS-4-HYDROXY-4-(5-THIAZOLYL)CYCLOHEXYL)-3-AZETIDINYL)AMINO)-2-OXOETHYL)-3-(TRIFLUOROMETHYL)
Preferred Name English
JNJ-41443532
Common Name English
Code System Code Type Description
CAS
1228650-83-6
Created by admin on Mon Mar 31 22:53:45 GMT 2025 , Edited by admin on Mon Mar 31 22:53:45 GMT 2025
PRIMARY
PUBCHEM
46208367
Created by admin on Mon Mar 31 22:53:45 GMT 2025 , Edited by admin on Mon Mar 31 22:53:45 GMT 2025
PRIMARY
SMS_ID
300000051572
Created by admin on Mon Mar 31 22:53:45 GMT 2025 , Edited by admin on Mon Mar 31 22:53:45 GMT 2025
PRIMARY
FDA UNII
0OJB0LES1A
Created by admin on Mon Mar 31 22:53:45 GMT 2025 , Edited by admin on Mon Mar 31 22:53:45 GMT 2025
PRIMARY
DRUG BANK
DB12632
Created by admin on Mon Mar 31 22:53:45 GMT 2025 , Edited by admin on Mon Mar 31 22:53:45 GMT 2025
PRIMARY